Schrödinger (SDGR) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Speaker0 Thank you for standing by. Welcome to Schrodinger's Conference Call to Review First Quarter twenty twenty five Financial Results. My name is Calvin, and I will be your operator for today's call. Please be advised that this call is being recorded at the company's request. Now I would like to introduce your host for today's conference, Ms. Sharon Madden, Senior Vice President of Investor Relations and Corporate Affairs. Please go ahead ...

Nurix’s DEL-AI platform uses a first-in-class DEL Foundation Model trained on the Company’s proprietary DNA encoded library data Nurix’s DEL Foundation Model can accurately predict novel binders to therapeutically relevant targets, including many targets considered undruggable, with the potential to accelerate the discovery of novel drugs SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, developmen ...